Karah Herdman Parschauer Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Karah Herdman Parschauer is EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 57,981 shares of RARE, which is worth approximately $2.59 Million. The most recent transaction as insider was on Jun 12, 2024, when has been sold 9,806 shares (Common Stock) at a price of $45.0 per share, resulting in proceeds of $441,270. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 58K

0% 3M change

11.54% 12M change

Total Value Held $2.59 Million

Karah Herdman Parschauer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 12 2024	SELL Open market or private sale	$441,270 $45.0 p/Share	9,806 Reduced 14.47%	57,981 Common Stock
Mar 01 2024	SELL Open market or private sale	$201,922 $53.76 p/Share	3,756 Reduced 5.28%	67,340 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	18,757 Added 20.96%	70,739 Common Stock
May 04 2023	SELL Open market or private sale	$197,010 $45.0 p/Share	4,378 Reduced 7.77%	51,982 Common Stock
Mar 01 2023	SELL Open market or private sale	$143,035 $45.25 p/Share	3,161 Reduced 5.33%	56,139 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	24,663 Added 29.44%	59,101 Common Stock
Mar 07 2022	SELL Open market or private sale	$323,563 $62.95 p/Share	5,140 Reduced 12.99%	34,438 Common Stock
Mar 01 2022	SELL Open market or private sale	$192,265 $66.62 p/Share	2,886 Reduced 10.18%	25,472 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	14,000 Added 26.13%	39,578 Common Stock
Oct 14 2021	SELL Open market or private sale	$25,153 $81.14 p/Share	310 Reduced 1.08%	28,358 Common Stock
Sep 08 2021	SELL Open market or private sale	$738,368 $100.65 p/Share	7,336 Reduced 20.38%	28,668 Common Stock
Sep 08 2021	BUY Exercise of conversion of derivative security	$399,812 $54.5 p/Share	7,336 Added 16.93%	36,004 Common Stock
Jun 10 2021	SELL Open market or private sale	$132,900 $100.0 p/Share	1,329 Reduced 4.43%	28,668 Common Stock
May 06 2021	SELL Open market or private sale	$35,579 $113.67 p/Share	313 Reduced 1.03%	29,997 Common Stock
Mar 01 2021	SELL Open market or private sale	$548,535 $138.17 p/Share	3,970 Reduced 11.61%	30,227 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	10,136 Added 22.86%	34,197 Common Stock
Oct 30 2020	SELL Open market or private sale	$991,488 $100.12 p/Share	9,903 Reduced 29.16%	24,061 Common Stock
Oct 30 2020	BUY Exercise of conversion of derivative security	$539,714 $54.5 p/Share	9,903 Added 22.62%	33,871 Common Stock
Oct 28 2020	SELL Open market or private sale	$9,700 $100.0 p/Share	97 Reduced 0.4%	23,968 Common Stock
Oct 28 2020	BUY Exercise of conversion of derivative security	$5,286 $54.5 p/Share	97 Added 0.4%	24,065 Common Stock
Oct 14 2020	SELL Open market or private sale	$28,600 $88.0 p/Share	325 Reduced 1.34%	23,968 Common Stock
Oct 08 2020	SELL Open market or private sale	$950,000 $95.0 p/Share	10,000 Reduced 29.16%	24,293 Common Stock
Oct 08 2020	BUY Exercise of conversion of derivative security	$545,000 $54.5 p/Share	10,000 Added 22.58%	34,293 Common Stock
Oct 06 2020	SELL Open market or private sale	$900,000 $90.0 p/Share	10,000 Reduced 29.16%	24,293 Common Stock
Oct 06 2020	BUY Exercise of conversion of derivative security	$484,300 $48.43 p/Share	10,000 Added 22.58%	34,293 Common Stock

Also insider at

EOLS

Evolus, Inc. Healthcare

Director

ARCT

Arcturus Therapeutics Holdings Inc. Healthcare

Director

TNYA

Tenaya Therapeutics, Inc. Healthcare

ANEB

Anebulo Pharmaceuticals, Inc. Healthcare

Director

KHP